Rocket Pharmaceuticals (RCKT) Change in Acquisitions & Divestments (2016 - 2026)

Rocket Pharmaceuticals (RCKT) has 10 years of Change in Acquisitions & Divestments data on file, last reported at $66.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 19.46% year-over-year to $66.2 million; the trailing twelve-month figure through Mar 2026 stood at $364.8 million (changed 0.01% YoY), and the FY2025 full-year result was $380.8 million, down 0.7% from the prior year.
• Change in Acquisitions & Divestments slipped to $66.2 million in Q1 2026, from $91.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $123.0 million in Q3 2025 to a low of $50.8 million in Q4 2022.
• A 5-year average of $83.1 million and a median of $82.3 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments decreased 23.97% in 2023 and jumped 62.05% in 2024, its largest moves.
• Tracing RCKT's Change in Acquisitions & Divestments over 5 years: stood at $50.8 million in 2022, then soared by 42.35% to $72.3 million in 2023, then climbed by 19.54% to $86.5 million in 2024, then advanced by 5.22% to $91.0 million in 2025, then decreased by 27.2% to $66.2 million in 2026.
• Business Quant data shows RCKT's Change in Acquisitions & Divestments at $66.2 million in Q1 2026, $91.0 million in Q4 2025, and $123.0 million in Q3 2025.